NCT03865290View on ClinicalTrials.gov

Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 2, 2019

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
IndigestionDiabetes Mellitus
Interventions
DRUG

Ondansetron 8mg

Oral Ondansetron 8 mg

DRUG

Placebo

Oral matched placebo

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER

NCT03865290 - Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia | Biotech Hunter | Biotech Hunter